In 2017, US regulators designated CTL019 as a "breakthrough therapy" and put the experimental immunotherapy agent on the fast track to market approval.
2017年,美国监管机构认定CTL019为“突破性的疗法”,并迅速将这种实验性的免疫疗法推向市场准入阶段。
It was the first cancer immunotherapy to receive the breakthrough designation. More are expected to follow in the coming years as the field of immunotherapy grows.
这是首个被称为“突破性”的癌症免疫疗法。随着免疫疗法领域的发展,我们有希望在未来看到更多突破性的疗法诞生。
【首个白血病治疗基因疗法在美获批】相关文章:
★ 健康补品西芹汁
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15